Obesity Drug Developer Corxel to List on Nasdaq in $377 Million SPAC Deal

Corxel Pharmaceuticals, a developer of treatments for obesity, will go public in the U.S. by merging with special purpose acquisition company (SPAC) Amanat Acquisition Corp. The companies announced the deal on Monday, which is designed to fund the development of Corxel's drug pipeline.

Deal Structure and Financing

The transaction is expected to provide Corxel with approximately $377 million in gross proceeds. This total includes funds from the SPAC and a concurrent $300 million private investment in public equity (PIPE) committed by institutional investors.

Key details of the agreement include:

• The deal is anticipated to close in the first half of 2027.
• The combined company is expected to be listed on the Nasdaq stock exchange.
• Leerink Partners served as the lead placement agent for the PIPE financing, with Evercore ISI, Guggenheim Securities, Cantor, and LifeSci Capital also acting as placement agents.

Strategic Rationale

Ad

This move allows Corxel to tap public markets amid a surge of investment in the weight-loss drug sector, a market currently dominated by industry giants Novo Nordisk and Eli Lilly. The capital raised is intended to advance Corxel's portfolio of oral product candidates.

The company's lead candidate, CX11, is being developed for obesity, type 2 diabetes, and related cardiometabolic conditions. According to the announcement, the funds will help advance CX11 into late-stage clinical development.

Market Context

A SPAC, or blank-check company, is a shell corporation that raises capital through an initial public offering (IPO) with the purpose of acquiring an existing private company, thereby taking it public. This alternative path to a traditional IPO has been used by numerous companies in the biotech sector to access funding for research and development.